| Cvs Pharmacy #16743 | |
| 371 Putnam Pike, Ste A-250, Smithfield, Rhode Island 02917 | |
| (401) 232-2854 |
| Name | Cvs Pharmacy #16743 |
|---|---|
| Organization Name | Rhode Island Cvs Pharmacy, L.l.c |
| Location | 371 Putnam Pike, Ste A-250, Smithfield, Rhode Island 02917 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (401) 232-2854 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Everist Genomics today announced the worldwide commercial availability of its OncoDefender-CRC colorectal cancer assay, the first and only molecular prognostic test capable of accurately predicting the risk of recurrence of cancer in patients previously treated with surgical resection of a Stage I/II colon cancer tumor or Stage I rectal cancer tumor.
Reporting for Kaiser Health News, in collaboration with The New York Times, Susan Okie writes: "Doctors in training have traditionally been insulated from information about the cost of the tests and treatments they order for patients — in fact, for decades, the subject was virtually taboo when professors and trainees discussed treatment decisions during hospital rounds.
In one of the big NHS blunders, nearly 800,000 people who have pledged one or more of their organs for donation may have had their preferences of which organ/s recorded incorrectly for the past 10 years. There are nearly 17 million donors who consent to give all their organs. However some have preferences and withhold consent for some organs like eyes, skin or heart etc. Some had also expressed their wish that their body tissue should not be used in research after their death. This huge error came to public notice in 2009 when the NHS Blood and Transplant started sending out mails to potential donors to check their preferences. Many people wrote back that the information in the records were not right.
Colorectal cancer (CRC) is the second most frequent cause of cancer-related mortality in both Europe and the United States. Treatment for patients with resectable hepatic metastases from colorectal cancer consists of surgery combined with chemotherapy, but recurrence is observed in two thirds of these patients.
A new multi-institution study led by Fergus Couch, Ph.D., a Mayo Clinic pathologist, provides more accurate estimates of breast cancer risk for U.S. women who harbor inherited mutations in breast cancer predisposition genes.
› Verified 1 days ago
| NPI Number | 1346262086 |
| Organization Name | RHODE ISLAND CVS PHARMACY LLC |
| Doing Business As | CVS PHARMACY #16743 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 371 Putnam Pike Ste A-250, Smithfield, RI 02917 |
| Phone Number | 401-232-2854 |
News Archive
Everist Genomics today announced the worldwide commercial availability of its OncoDefender-CRC colorectal cancer assay, the first and only molecular prognostic test capable of accurately predicting the risk of recurrence of cancer in patients previously treated with surgical resection of a Stage I/II colon cancer tumor or Stage I rectal cancer tumor.
Reporting for Kaiser Health News, in collaboration with The New York Times, Susan Okie writes: "Doctors in training have traditionally been insulated from information about the cost of the tests and treatments they order for patients — in fact, for decades, the subject was virtually taboo when professors and trainees discussed treatment decisions during hospital rounds.
In one of the big NHS blunders, nearly 800,000 people who have pledged one or more of their organs for donation may have had their preferences of which organ/s recorded incorrectly for the past 10 years. There are nearly 17 million donors who consent to give all their organs. However some have preferences and withhold consent for some organs like eyes, skin or heart etc. Some had also expressed their wish that their body tissue should not be used in research after their death. This huge error came to public notice in 2009 when the NHS Blood and Transplant started sending out mails to potential donors to check their preferences. Many people wrote back that the information in the records were not right.
Colorectal cancer (CRC) is the second most frequent cause of cancer-related mortality in both Europe and the United States. Treatment for patients with resectable hepatic metastases from colorectal cancer consists of surgery combined with chemotherapy, but recurrence is observed in two thirds of these patients.
A new multi-institution study led by Fergus Couch, Ph.D., a Mayo Clinic pathologist, provides more accurate estimates of breast cancer risk for U.S. women who harbor inherited mutations in breast cancer predisposition genes.
› Verified 1 days ago
News Archive
Everist Genomics today announced the worldwide commercial availability of its OncoDefender-CRC colorectal cancer assay, the first and only molecular prognostic test capable of accurately predicting the risk of recurrence of cancer in patients previously treated with surgical resection of a Stage I/II colon cancer tumor or Stage I rectal cancer tumor.
Reporting for Kaiser Health News, in collaboration with The New York Times, Susan Okie writes: "Doctors in training have traditionally been insulated from information about the cost of the tests and treatments they order for patients — in fact, for decades, the subject was virtually taboo when professors and trainees discussed treatment decisions during hospital rounds.
In one of the big NHS blunders, nearly 800,000 people who have pledged one or more of their organs for donation may have had their preferences of which organ/s recorded incorrectly for the past 10 years. There are nearly 17 million donors who consent to give all their organs. However some have preferences and withhold consent for some organs like eyes, skin or heart etc. Some had also expressed their wish that their body tissue should not be used in research after their death. This huge error came to public notice in 2009 when the NHS Blood and Transplant started sending out mails to potential donors to check their preferences. Many people wrote back that the information in the records were not right.
Colorectal cancer (CRC) is the second most frequent cause of cancer-related mortality in both Europe and the United States. Treatment for patients with resectable hepatic metastases from colorectal cancer consists of surgery combined with chemotherapy, but recurrence is observed in two thirds of these patients.
A new multi-institution study led by Fergus Couch, Ph.D., a Mayo Clinic pathologist, provides more accurate estimates of breast cancer risk for U.S. women who harbor inherited mutations in breast cancer predisposition genes.
› Verified 1 days ago
Cvs Pharmacy #16743 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 371 Putnam Pike, Smithfield, Rhode Island 02917 Phone: (401) 232-2854 | |
Ocean State Urgent Care Center Of S Type: Medicare Supplier Location: 400 Putnam Pike, Smithfield, Rhode Island 02917 Phone: (401) 757-6160 |